Chimerix has a strong commitment to pursuing collaborations with external organizations
that will result in improvements in patient care.

Chimerix’s proprietary lipid conjugate technology has enabled the discovery of two novel, orally available nucleotide analogs: brincidofovir (CMX001), our lead clinical-stage molecule, and CMX157, which was licensed to ContraVir Pharmaceuticals in 2014. Both of these molecules are chemically modified versions of antiviral drugs that were previously available only in intravenous form, cidofovir in the case of brincidofovir and tenofovir in the case of CMX157. Through the application of our lipid conjugate technology, we have been able to transform the profile of both of these molecules. We welcome opportunities to explore collaborations that could result in the discovery of other similar orally available molecules.

We are also actively seeking collaborations aimed at augmenting our own discovery programs and development pipeline. We are particularly interested in bringing additional solutions to those patient populations we serve. Such areas of interest include the following:

  • Stem cell transplantation
  • Solid organ transplantation
  • Specialty/critical care infectious diseases
  • Hematology-oncology

Key benefits of collaborating with Chimerix include:

  • Strong culture of innovation
  • Extensive clinical development and regulatory experience
  • Commercial group with proven track record of successful product launches
  • Creativity in constructing partnerships
  • Commitment to professional alliance management
  • Public company infrastructure


In 2011, Chimerix initiated a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure to treat smallpox outbreaks in the event of a bioterror attack or accidental release. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus and smallpox.


CMX157 is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. CMX157 is active against hepatitis B virus (HBV) and more than 200-fold more potent in vitro versus tenofovir against all major HIV subtypes resistant to current therapies. CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. It has been evaluated in a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile.In 2014, we entered into a license agreement with ContraVir Pharmaceuticals regarding CMX157. ContraVir intends to develop CMX157 as a potential treatment for HBV and HIV.

To learn more about partnering with Chimerix or to initiate a conversation, please contact our Business Development group:

Commitment to Those We Serve

At Chimerix, we believe it is critical that scientists, medical professionals, and researchers work together on disease prevention, diagnosis and management. That’s why we offer support, resources and funding.

Our funding focus areas are:

  • Charitable contributions
  • Research grants
  • Third-party educational grants
  • Third-party scientific grants

Charitable Contributions. Chimerix provides charitable contributions, including both direct funding and no-charge product, to 501(c)(3) tax-exempt charitable organizations to assist such organizations in achieving their charitable missions.

Research Grants. From time-to-time, Chimerix will provide grants to third parties to allow these entities to conduct self-instituted, bona fide medical research aimed at enhancing general scientific knowledge, professional skills and disease awareness. Such research may be of legitimate interest to Chimerix and therefore may be supported through a research grant. A consulting or service agreement is not required in this context, because the researcher is not performing services on Chimerix’s behalf. Rather, the research grant is set forth in a written agreement signed by the grant recipient and Chimerix.

Third-Party Educational Grants. Chimerix provides funds to sponsor third-party educational programs where certain conditions are met. These programs are conducted by independent, accredited continuing medical education (“CME”) providers and are designed to assist physicians and other professionals in obtaining information that can contribute to the improvement of patient care. Chimerix’s support of CME programs is not intended to promote a particular treatment.

Third-Party Scientific Grants. Chimerix provides funds to sponsor third-party scientific conferences and seminars where certain conditions are met. These activities are conducted by independent providers and are designed to assist physicians and other professionals in obtaining information that can contribute to the improvement of patient care. Chimerix’s support is not intended to promote a particular treatment.

Apply for funding by e-mailing: